Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D

Executive Summary

Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers
Advertisement

Related Content

Actavis Buying Spree Includes Alpharma In Race For Generic Top Three
Actavis Buying Spree Includes Alpharma In Race For Generic Top Three
Generic Industry Faces Consolidation As Indian Firms Look To Enter U.S.
Generic Industry Faces Consolidation As Indian Firms Look To Enter U.S.
GPhA Medicaid Reform Goals Include Substitution Incentives, WAMP Pricing
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Merck Reconsiders Legal Strategy: Will Settlements Ease Vioxx Pain?
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
King Says It Can Grow On Its Own Following Collapse Of Mylan Merger Plans
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions

Topics

Advertisement
UsernamePublicRestriction

Register

PS046408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel